Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country symbols : Scyx save search
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
Published: 2023-05-19 (Crawled : 16:00) - biospace.com/
TTOO 4 | $2.76 1.47% 1.45% 320K
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: -0.36%
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: -0.7%
H: 0.18%
C: -1.4%
institute research global pathogens response
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
Published: 2023-04-13 (Crawled : 14:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 0.0%
H: 9.42%
C: -1.62%
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Published: 2023-03-30 (Crawled : 18:00) - biospace.com/
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.65%
C: 0.6%
SPRO | $1.41 -1.74% -1.77% 110K
|
Health Technology
|
| O: 2.07%
H: 0.0%
C: -2.7%
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 71.86%
H: 3.48%
C: 2.44%
infection agreement brexafemme fungal infection
SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
Published: 2022-11-30 (Crawled : 14:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 2.52%
H: 0.0%
C: -3.28%
scy-247 reserve grant health study
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: -1.79%
H: 2.27%
C: -18.18%
financial update results
SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
Published: 2022-11-01 (Crawled : 13:20) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 2.16%
H: 2.97%
C: -5.51%
report financial update results
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Published: 2022-10-24 (Crawled : 13:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -7.11%
ongoing infections positive study fungal infection
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 1.58%
H: 12.84%
C: 7.0%
meeting infections positive study
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-05-12 (Crawled : 12:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: -8.59%
H: 9.39%
C: 3.31%
results
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published: 2022-05-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: -4.04%
ongoing phase 3
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
Published: 2022-04-19 (Crawled : 13:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: -0.31%
H: 2.48%
C: 1.55%
brexafemme insurance
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-11-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K
|
Health Technology
|
| O: 3.57%
H: 0.0%
C: -4.71%
financial results results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.